LITTLE KNOWN FACTS ABOUT AI IN CELL AND GENE THERAPY MARKET BY TECHNOLOGY, BY INDICATION, BY APPLICATION, BY END-USER (BIOPHARMACEUTICAL COMPANIES, RESEARCH INSTITUTES, HEALTHCARE PROVIDERS) AND BY REGION.

g., excellent control and merchandise release). In this sort of use situations, There may be reduced tolerance for mistake, given that the accuracy in these ways is straight connected to affected individual basic safety. This is likely to entice higher regulatory scrutiny, presenting added hurdles and uncertainty to AI implementation. Gene- and RN